(2017). Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo. Circulation. http://doi.org/10.1161/circulationaha.117.029190
. M. Kosiborod
First name
M.
Last name
Kosiborod
(2018). SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol. http://doi.org/10.1016/j.jacc.2018.01.085
. (2019). Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. Am J Nephrol. http://doi.org/10.1159/000504558
. (2020). Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(19)30384-5
.